- Home
- CCU vs IBRX Comparison
CCU vs IBRX Comparison
Compare CCU & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCU
- IBRX
- Stock Information
- Founded
- CCU 1850
- IBRX 2014
- Country
- CCU Chile
- IBRX United States
- Employees
- CCU N/A
- IBRX N/A
- Industry
- CCU Beverages (Production/Distribution)
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCU Consumer Staples
- IBRX Health Care
- Exchange
- CCU Nasdaq
- IBRX Nasdaq
- Market Cap
- CCU 2.4B
- IBRX 2.3B
- IPO Year
- CCU 1992
- IBRX N/A
- Fundamental
- Price
- CCU $12.36
- IBRX $2.40
- Analyst Decision
- CCU Strong Sell
- IBRX Strong Buy
- Analyst Count
- CCU 1
- IBRX 5
- Target Price
- CCU $9.40
- IBRX $10.20
- AVG Volume (30 Days)
- CCU 175.5K
- IBRX 9.0M
- Earning Date
- CCU 11-05-2025
- IBRX 08-05-2025
- Dividend Yield
- CCU 2.45%
- IBRX N/A
- EPS Growth
- CCU 38.53
- IBRX N/A
- EPS
- CCU 0.44
- IBRX N/A
- Revenue
- CCU $3,254,866,554.00
- IBRX $56,600,000.00
- Revenue This Year
- CCU $10.29
- IBRX $629.94
- Revenue Next Year
- CCU $4.48
- IBRX $109.91
- P/E Ratio
- CCU $13.96
- IBRX N/A
- Revenue Growth
- CCU 19.82
- IBRX 4227.22
- 52 Week Low
- CCU $10.03
- IBRX $1.83
- 52 Week High
- CCU $15.75
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- CCU 52.02
- IBRX 47.34
- Support Level
- CCU $12.10
- IBRX $2.29
- Resistance Level
- CCU $12.34
- IBRX $2.47
- Average True Range (ATR)
- CCU 0.21
- IBRX 0.12
- MACD
- CCU 0.02
- IBRX 0.02
- Stochastic Oscillator
- CCU 44.30
- IBRX 60.53
About CCU Compania Cervecerias Unidas S.A.
United Breweries Co Inc is a multi-category beverage company with operations in Chile, Argentina, Bolivia, Colombia, Paraguay and Uruguay. The company is a player in each one of the beverage categories in which it participates in Chile, including beer, soft drinks, mineral and bottled water, juice, wine, cider and pisco, among others. The Company has three operating segment with respect to its revenues in the geographic areas of commercial activity: Chile; International business and Wine. It generates maximum revenue from Chile.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.